BIONANO GENOMICS INC (BNGO) Fundamental Analysis & Valuation

NASDAQ:BNGO • US09075F4046

1.13 USD
+0.01 (+0.89%)
At close: Mar 10, 2026
1.14 USD
+0.01 (+0.88%)
After Hours: 3/10/2026, 8:08:58 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BNGO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

BNGO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. BNGO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BNGO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. BNGO Profitability Analysis

1.1 Basic Checks

  • In the past year BNGO has reported negative net income.
  • In the past year BNGO has reported a negative cash flow from operations.
  • BNGO had negative earnings in each of the past 5 years.
  • BNGO had a negative operating cash flow in each of the past 5 years.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • The Return On Assets of BNGO (-48.81%) is worse than 82.46% of its industry peers.
  • BNGO has a worse Return On Equity (-77.49%) than 77.19% of its industry peers.
Industry RankSector Rank
ROA -48.81%
ROE -77.49%
ROIC N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • BNGO has a Gross Margin (45.97%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of BNGO has declined.
  • The Profit Margin and Operating Margin are not available for BNGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BNGO Health Analysis

2.1 Basic Checks

  • BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BNGO has less shares outstanding
  • The number of shares outstanding for BNGO has been reduced compared to 5 years ago.
  • Compared to 1 year ago, BNGO has a worse debt to assets ratio.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • BNGO has an Altman-Z score of -13.14. This is a bad value and indicates that BNGO is not financially healthy and even has some risk of bankruptcy.
  • BNGO has a Altman-Z score of -13.14. This is amonst the worse of the industry: BNGO underperforms 87.72% of its industry peers.
  • BNGO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.07, BNGO is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -13.14
ROIC/WACCN/A
WACC64.41%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • BNGO has a Current Ratio of 2.12. This indicates that BNGO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BNGO (2.12) is comparable to the rest of the industry.
  • BNGO has a Quick Ratio of 1.82. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.82, BNGO perfoms like the industry average, outperforming 43.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.12
Quick Ratio 1.82
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BNGO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 77.75% over the past year.
  • Looking at the last year, BNGO shows a very negative growth in Revenue. The Revenue has decreased by -13.84% in the last year.
  • BNGO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.89% yearly.
EPS 1Y (TTM)77.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.38%
Revenue 1Y (TTM)-13.84%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-9.75%

3.2 Future

  • BNGO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.92% yearly.
  • The Revenue is expected to grow by 22.69% on average over the next years. This is a very strong growth
EPS Next Y92.31%
EPS Next 2Y39.87%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue Next Year-2.01%
Revenue Next 2Y10.35%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -500 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. BNGO Valuation Analysis

4.1 Price/Earnings Ratio

  • BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BNGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BNGO's earnings are expected to grow with 25.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y25.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNGO Dividend Analysis

5.1 Amount

  • BNGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNGO Fundamentals: All Metrics, Ratios and Statistics

BIONANO GENOMICS INC

NASDAQ:BNGO (3/10/2026, 8:08:58 PM)

After market: 1.14 +0.01 (+0.88%)

1.13

+0.01 (+0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners10.61%
Inst Owner Change262.17%
Ins Owners3.19%
Ins Owner Change0%
Market Cap11.50M
Revenue(TTM)28.72M
Net Income(TTM)-38.59M
Analysts80
Price Target7.65 (576.99%)
Short Float %12.85%
Short Ratio5.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.8%
Min EPS beat(2)18.39%
Max EPS beat(2)19.21%
EPS beat(4)3
Avg EPS beat(4)-14.6%
Min EPS beat(4)-158.66%
Max EPS beat(4)62.68%
EPS beat(8)6
Avg EPS beat(8)-2.56%
EPS beat(12)6
Avg EPS beat(12)-5.17%
EPS beat(16)7
Avg EPS beat(16)-8.67%
Revenue beat(2)1
Avg Revenue beat(2)0.88%
Min Revenue beat(2)-3.37%
Max Revenue beat(2)5.12%
Revenue beat(4)3
Avg Revenue beat(4)8.1%
Min Revenue beat(4)-3.37%
Max Revenue beat(4)29.08%
Revenue beat(8)5
Avg Revenue beat(8)3.75%
Revenue beat(12)8
Avg Revenue beat(12)2.71%
Revenue beat(16)11
Avg Revenue beat(16)3.13%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.24%
EPS NY rev (1m)0%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-20.56
EYN/A
EPS(NY)-3.64
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.82
BVpS4.89
TBVpS4.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.81%
ROE -77.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.97%
FCFM N/A
ROA(3y)-99.22%
ROA(5y)-76.96%
ROE(3y)-203.87%
ROE(5y)-150.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-61.43%
GM growth 5Y-48.22%
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.12
Quick Ratio 1.82
Altman-Z -13.14
F-Score4
WACC64.41%
ROIC/WACCN/A
Cap/Depr(3y)12.46%
Cap/Depr(5y)12.34%
Cap/Sales(3y)4.56%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.38%
EPS Next Y92.31%
EPS Next 2Y39.87%
EPS Next 3Y25.68%
EPS Next 5Y14.92%
Revenue 1Y (TTM)-13.84%
Revenue growth 3Y19.62%
Revenue growth 5Y24.89%
Sales Q2Q%-9.75%
Revenue Next Year-2.01%
Revenue Next 2Y10.35%
Revenue Next 3Y21.7%
Revenue Next 5Y22.69%
EBIT growth 1Y59.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.38%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.63%
OCF growth 3YN/A
OCF growth 5YN/A

BIONANO GENOMICS INC / BNGO FAQ

Can you provide the ChartMill fundamental rating for BIONANO GENOMICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to BNGO.


Can you provide the valuation status for BIONANO GENOMICS INC?

ChartMill assigns a valuation rating of 1 / 10 to BIONANO GENOMICS INC (BNGO). This can be considered as Overvalued.


Can you provide the profitability details for BIONANO GENOMICS INC?

BIONANO GENOMICS INC (BNGO) has a profitability rating of 0 / 10.


What is the financial health of BIONANO GENOMICS INC (BNGO) stock?

The financial health rating of BIONANO GENOMICS INC (BNGO) is 4 / 10.